Document is current
Any future updates will be listed below
-
Authors
Li, Caifeng
Zhang, Junmei
Yu, Haiguo
Lu, Meiping
Yang, Sirui
Liu, Cuihua
Zeng, Ping
Zhao, Bo
Li, Xiaoqing
Zheng, Wenjie
Du, Yue
Zhang, Wei
Li, Zhihui
Hu, Xiufen
Lai, Jianming
Xu, Qian
Zhang, Xu
Wang, Xianyang
Adili, Palasaiti
Qu, Wei
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05925452 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study
https://doi.org/10.1007/s40744-026-00830-9
-
Funding
Funding for this research was provided by:
Changchun GeneScience Pharmaceutical Co., Ltd.
- License Information
-
More Information
Article History
Received: 17 December 2025
Accepted: 4 February 2026
First Online: 11 March 2026
Declarations
:
: Qian Xu, Xu Zhang, Xianyang Wang, Palasaiti Adili and Wei Qu are employees of Changchun GeneScience Pharmaceutical Co., Ltd. Caifeng Li, Junmei Zhang, Haiguo Yu, Meiping Lu, Sirui Yang, Cuihua Liu, Ping Zeng, Bo Zhao, Xiaoqing Li, Wenjie Zheng, Yue Du, Wei Zhang, Zhihui Li, Xiufen Hu, and Jianming Lai declare that they have no competing interests.
: The study was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation (ICH) Guidelines for Good Clinical Practice, and applicable regulatory requirements in China. Ethics approval was obtained from the medical ethics committee of Beijing Children’s Hospital, Capital Medical University (Approval No. [2023]-Y-019-A), as well as by the institutional review boards of all participating centers prior to study initiation (Supplementary Table S1). Written informed consent was obtained from the parents or legal guardians of all participants, and assent was obtained from participants as required by local regulations.
